<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091286</url>
  </required_header>
  <id_info>
    <org_study_id>9976</org_study_id>
    <secondary_id>UVACC-GI37</secondary_id>
    <secondary_id>UVACC-23302</secondary_id>
    <nct_id>NCT00091286</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer</brief_title>
  <official_title>Evaluation of the Immunogenicity of Vaccination With HER-2/Neu and CEA Derived Synthetic Peptides With GM-CSF-in-Adjuvant, in Patients With Stage IIB, III, or IV Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may make the body build an immune response to kill
      tumor cells.

      PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients
      with stage IIB, stage III, or stage IV colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether vaccination comprising HER-2-neu and carcinoembryonic antigen
           synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 causes an immune
           response in patients with stage IIB, III, or IV colorectal cancer.

        -  Determine the safety of this regimen in these patients.

      OUTLINE: Patients receive vaccination comprising HER-2-neu and carcinoembryonic antigen
      synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 on days 1, 8, and 15. On day
      22, patients undergo removal of the lymph node into which the vaccination site drains to
      determine whether the immune system is responding to the vaccine.

      PROJECTED ACCRUAL: A maximum of 15 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accruals
  </why_stopped>
  <start_date type="Actual">March 24, 2003</start_date>
  <completion_date type="Actual">February 15, 2008</completion_date>
  <primary_completion_date type="Actual">February 15, 2008</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the 4-peptide mixture</measure>
    <time_frame>30 days following last vaccine</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with an immune response to the peptides</measure>
    <time_frame>through Day 22</time_frame>
    <description>T cell responses against the peptides as measured in the sentinel immunized node</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of the peptide mixture measured in the peripheral blood</measure>
    <time_frame>through Day 22</time_frame>
    <description>T cell responses against the peptides and/or tumor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Peptide Vaccine + Montanide + GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine</intervention_name>
    <arm_group_label>Peptide Vaccine + Montanide + GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of colorectal cancer

               -  Stage IIB, III, or IV disease

          -  HLA-A2- or -A3-positive

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count &gt; 1,000/mm^3

          -  Hemoglobin &gt; 9 g/dL

          -  Platelet count &gt; 100,000/mm^3

        Hepatic

          -  Liver function tests ≤ 2.5 times upper limit of normal (ULN)

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Cardiovascular

          -  No New York Heart Association class III or IV heart disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known or suspected allergies to any component of the study drug

          -  No active connective tissue disease requiring medications

          -  No systemic autoimmune disease with visceral involvement

          -  No uncontrolled diabetes

          -  No other severe autoimmune disease

          -  No medical contraindication or potential problem that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 30 days since prior immunotherapy

          -  More than 30 days since prior growth factors

          -  More than 30 days since prior allergy shots

          -  No prior vaccination with any study peptides for malignancy

        Chemotherapy

          -  More than 30 days since prior chemotherapy

        Endocrine therapy

          -  More than 30 days since prior steroids

        Radiotherapy

          -  More than 30 days since prior radiotherapy

        Surgery

          -  More than 30 days since prior surgery

        Other

          -  At least 30 days, but ≤ 24 months, since prior therapy for colorectal cancer

          -  No concurrent illegal drug use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M. Friel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Director, Human Immune Therapy Center</investigator_title>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IIB colon cancer</keyword>
  <keyword>stage IIIA colon cancer</keyword>
  <keyword>stage IIIB colon cancer</keyword>
  <keyword>stage IIIC colon cancer</keyword>
  <keyword>stage IVA colon cancer</keyword>
  <keyword>stage IVB colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IIB rectal cancer</keyword>
  <keyword>stage IIIA rectal cancer</keyword>
  <keyword>stage IIIB rectal cancer</keyword>
  <keyword>stage IIIC rectal cancer</keyword>
  <keyword>stage IVA rectal cancer</keyword>
  <keyword>stage IVB rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

